wegovy

Starting July 2026, Cigna is drawing a line in the sand by discontinuing coverage for popular weight-loss medications like wegovy and Zepbound for its employees. Citing rising expenses and available alternatives, this decision reflects a broader trend among employers weighing the financial implications of such costly treatments. It's noteworthy that coverage for diabetes patients will continue to remain unaffected.

German researchers are making waves with a cutting-edge 'Trojan horse' obesity drug that has eclipsed current frontrunners in trials with mice. The innovative formula decreases appetite and weight significantly while also enhancing blood sugar levels and insulin sensitivity. Utilizing hormone mimics for precise cellular targeting, this approach minimizes unwanted side effects and presents a multifaceted method for combating obesity.

Polycystic ovary syndrome (PCOS) is now polyendocrine metabolic ovarian syndrome (PMOS), reflecting its hormonal and metabolic nature. Research highlights its endocrine roots, impacting insulin and other hormones, not just ovaries. This reclassification aims for earlier diagnosis and better management, emphasizing metabolic health alongside reproductive concerns for affected women.

Experiencing hair loss while losing weight is a common physiological reaction as the body enters 'survival mode.' Rapid weight loss, often triggered by extreme diets or weight-loss medications, can push hair follicles into a resting phase. Let's know more about this issue.

Affordable generic versions of Ozempic and wegovy have quickly secured 20% of the Rs 1,600 crore weight-loss market following patent expiry. Early movers like Torrent and Sun Pharma are challenging Eli Lilly's Mounjaro, with generics and lower pricing boosting semaglutide's market position.

New research reveals genes influence weight loss and nausea from Ozempic and Mounjaro. A study of nearly 28,000 people found specific genetic variants predict drug effectiveness and side effects. This breakthrough could lead to personalized prescriptions, helping doctors tailor treatments for millions. Doctors may soon use genetic tests to set realistic expectations and choose the best drug for each patient.

As semaglutide’s patent expires on March 20 the entry of generics is set to nearly halve treatment costs, opening up injectable anti-obesity treatment. But pharma firms, trying to stand out in a crowded room, are looking beyond simple price cuts, eyeing an entire weight-loss ecosystem. This could include diet plans, counselling and clinic partnerships

The FDA has approved a daily pill version of Novo Nordisk's wegovy, offering an oral alternative to injectable weight-loss drugs. Containing semaglutide, the pill demonstrated similar weight loss and side-effect profiles to its injectable counterpart in clinical trials. This new option aims to expand access for patients who prefer not to use injections.

wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity and related metabolic issues. Experts emphasize it's not a quick fix but a tool to improve insulin function, reduce cardiac events, and aid those with diabetes and PCOS when combined with lifestyle changes.

Novo Nordisk has launched wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, wegovy is a once-weekly injectable using a user-friendly FlexTouch pen. Targeting India's large obese population, Novo Nordisk aims to capture a significant share of the ₹576 crore anti-obesity market.

Novo Nordisk's wegovy, a weight loss drug, will soon be accessible to US customers via telehealth platforms like Hims & Hers, LifeMD, and Ro, offering a reduced monthly price of $449.

Novo Nordisk has launched wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP.

Ozempic, Mounjaro and wegovy are now cultural symbols of weight loss. These medications help control blood sugar and aid weight loss. Ozempic is for type 2 diabetes. Mounjaro targets two hormone pathways for stronger sugar and weight control. wegovy is for obesity and related health issues. The choice depends on individual goals and medical history.

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took wegovy

A new study has revealed that GLP-1 drugs, commonly used for diabetes and weight loss, show promise in treating alcohol addiction. The research, published in JAMA Psychiatry, found that semaglutide and liraglutide may reduce alcohol cravings by influencing the brain's reward system.

A recent study presented at the EASD meeting in Vienna reveals that weight loss drugs like Ozempic, wegovy, and Mounjaro can alter taste perception. Around one in five users reported heightened sensitivity to sweetness or saltiness. Researchers suggest these taste changes may contribute to appetite control, potentially aiding in tailored dietary advice and improved treatment outcomes.

Novo Nordisk A/S is considering raising the sales guidance for its obesity drugs after a strong introduction for its new medication called wegovy, chief executive officer (CEO) Lars Fruergaard Jorgensen said in an interview.

Groundbreaking GLP-1 drugs like Ozempic, Mounjaro and wegovy are revolutionising weight loss, with studies showing significant results. While US prices are steep, Indian costs are considerably lower, making them accessible but still a substantial investment. Experts emphasize that these are not magic bullets, requiring ongoing use and medical guidance, raising questions about long-term affordability and access.

Costco is now offering Ozempic and wegovy at a discounted price of $499 per month for cash-paying members. This move aims to combat high drug costs and unsafe alternatives, making these popular diabetes and weight-loss medications more accessible. The program is rolling out to over 600 U.S. locations.

wegovy, a weight loss drug, is gaining popularity for its effectiveness, but experts emphasize that it's most successful when combined with a healthy lifestyle. Doctors at Mass General Brigham recommend a MEAL plan focusing on muscle maintenance with adequate protein, energy balance through mindful eating, managing side effects with dietary adjustments, and staying hydrated.

Supply problems and insurance complications are making it difficult for people to access and stay on weight-loss medications like wegovy, according to doctors and patients. Patients face challenges in finding pharmacies with the medication in stock and often have to make long drives to access it. Insurance coverage for these medications is also limited, with some Medicare and Medicaid programs not covering them and private insurers requiring pre-approval or proof of weight loss. However, experts believe that coverage may improve in the future as more employers consider covering obesity medicines.

Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk's patent expiry. This move significantly reduces therapy costs, offering patients greater access to treatment for obesity and type-2 diabetes. Torrent Pharma even introduced both oral and injectable versions, marking a significant step in addressing India's growing metabolic disorder crisis.

Novo Nordisk India MD expects wegovy’s price cut to lift patient uptake 5–7 times

A recent clinical trial reveals that wegovy, a popular weight-loss drug containing semaglutide, shows promising results in treating liver diseases like MASH. The study, published in the New England Journal of Medicine, involved over 800 participants across 37 countries. wegovy significantly reduced liver inflammation and scarring, offering hope for millions affected by fatty liver diseases.

Amy Schumer endorses the new weight loss drug Mounjaro, praising its effectiveness after an adverse experience with wegovy. Mounjaro is an injectable medication for type 2 diabetes known for its weight management benefits and is now gaining popularity in the United States.

wegovy is a higher dose version of the diabetes drug semaglutide. It was approved by the USFDA in June 2021 for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater.